Dizal (Jiangsu) Pharmaceutical Co., Ltd.
๐จ๐ณChina
- Country
- ๐จ๐ณChina
- Ownership
- Public
- Established
- 2017-10-27
- Employees
- 581
- Market Cap
- -
- Website
- http://www.dizalpharma.com
Clinical Trials
7
Active:3
Completed:2
Trial Phases
2 Phases
Phase 1:4
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)โข Click on a phase to view related trials
Phase 1
4 (66.7%)Not Applicable
1 (16.7%)phase_1_2
1 (16.7%)Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Not Applicable
Not yet recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Dizal (Jiangsu) Pharmaceutical Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT07079475
DZD9008 PK Study in Hepatic Impairment Subjects
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Dizal Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT06084104
- Locations
- ๐บ๐ธ
Orlando Clinical Research Center, Orlando, Florida, United States
๐บ๐ธAmerican Research Corporation, San Antonio, Texas, United States
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Dizal (Jiangsu) Pharmaceutical Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT05176873
- Locations
- ๐บ๐ธ
Frontage Clinical Service 200 Meadowlands Parkway, Secaucus, New Jersey, United States
News
No news found